Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent

Inclusion Criteria: * Patient must sign informed consent prior to the index-procedure * Patient must be older than 18 years * Patient must be compliant with follow-up dates at 1 month and 12 months * Patients with intermittent claudication (Rutherford 2-3) and critical limb ischemia (Rutherford 4-5) * Target lesion is located in the superficial femoral artery (minimal 1 cm from origin of SFA and minimal 1 cm above the edge of the patella) * Reference vessel diameter ≥4.5 and ≤6.5 mm (visual estimate) * Patients with a TASC A, B or C lesion * Diameter stenosis of target lesion \>50% or chronic occlusions * Inflow arteries are free of hemodynamically significant obstruction (i.e. ≥50%) * The popliteal artery (outflow) is free of hemodynamically significant obstruction (i.e. ≥50%) * At least 1 patent below-the-knee vessel (anterior tibial artery, posterior tibial artery or peroneal artery) till the ankle confirmed by baseline angiography Exclusion Criteria: * Patients with Rutherford 1 and 6 * Patiens with Serum creatinine \> 2.0 mg/dL or renal dialysis * Patient takes esomeprazole or omeprazole * Patient is pregnant * Patient suffers from acute limb ischemia defined as any sudden decrease in limb perfusion causing a potential threat to limb viability * Target lesion cannot be crossed with a guidewire * Target lesion is located in the popliteal artery * Patients with a nickel-titanium allergy * Patients with an aneurysm in the superficial femoral artery and popliteal artery * Patients with a TASC D lesion * Patients with a life expectancy \<1 year * Patients with scheduled elective non-vascular procedures within 3 months after index-procedure, vascular procedures are allowed within 3 months after index-procedure if it is guaranteed that acetylic salicylic acid and clopidogrel intake is not interrupted * Patients with previous bypass surgery in the SFA * Patients with intolerance to antithrombotic medication (acetylic salicylic acid, clopidogrel, ticlopidine, glycoprotein IIb/IIIa inhibitors, direct thrombin inhibitors, etc) * Patient has not been premedicated with acetylic salicylic acid (at least 80 mg/day) 2 hours before the index-procedure * Patient has not been premedicated with clopidogrel (600 mg/day) 2 hours before the index-procedure